LigaChem Biosciences Inc. (KOSDAQ:141080)
South Korea · Delayed Price · Currency is KRW 200,000
-1,500 (-0.74%)
Apr 24, 2026, 3:30 PM KST
LigaChem Biosciences Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 141,553 | 125,898 | 34,146 | 33,412 | 32,157 | |
Revenue Growth (YoY) | 12.44% | 268.71% | 2.20% | 3.90% | -44.07% |
Cost of Revenue | 15,557 | 15,950 | 16,348 | 15,563 | 14,459 |
Gross Profit | 125,996 | 109,948 | 17,797 | 17,849 | 17,698 |
Selling, General & Admin | 13,991 | 19,159 | 12,226 | 5,628 | 4,829 |
Research & Development | 216,908 | 113,186 | 79,609 | 51,110 | 39,071 |
Amortization of Goodwill & Intangibles | 2,003 | 1,464 | 1,556 | 1,526 | 1,490 |
Operating Expenses | 232,482 | 130,862 | 98,620 | 68,224 | 45,404 |
Operating Income | -106,486 | -20,913 | -80,822 | -50,375 | -27,707 |
Interest Expense | -883.19 | -503.21 | -528.26 | -285.75 | -68.77 |
Interest & Investment Income | 18,381 | 19,975 | 5,808 | 4,267 | 901.31 |
Earnings From Equity Investments | 1,280 | 840.1 | 838.1 | 52.28 | 120.25 |
Currency Exchange Gain (Loss) | -1,868 | 4,656 | 1,218 | 2,601 | 1,841 |
Other Non Operating Income (Expenses) | 126.32 | 448 | 4,815 | -1,655 | 4,081 |
EBT Excluding Unusual Items | -89,449 | 4,502 | -68,672 | -45,396 | -20,832 |
Gain (Loss) on Sale of Investments | -4,397 | 4,580 | -6,853 | -2,088 | 486.48 |
Gain (Loss) on Sale of Assets | 0.35 | 8.14 | 37.83 | 1.13 | -177.86 |
Asset Writedown | -45 | 35 | -260.19 | -301.66 | - |
Other Unusual Items | - | - | - | 61.98 | - |
Pretax Income | -93,890 | 9,125 | -75,747 | -47,723 | -20,523 |
Income Tax Expense | -2,338 | 1,325 | -2,043 | -2,631 | 2,868 |
Earnings From Continuing Operations | -91,552 | 7,800 | -73,704 | -45,092 | -23,391 |
Minority Interest in Earnings | 17,274 | - | - | - | - |
Net Income | -74,278 | 7,800 | -73,704 | -45,092 | -23,391 |
Net Income to Common | -74,278 | 7,800 | -73,704 | -45,092 | -23,391 |
Shares Outstanding (Basic) | 36 | 34 | 28 | 28 | 24 |
Shares Outstanding (Diluted) | 36 | 35 | 28 | 28 | 24 |
Shares Change (YoY) | 4.68% | 22.36% | 1.38% | 16.13% | 0.47% |
EPS (Basic) | -2041.71 | 226.52 | -2594.83 | -1609.47 | -969.59 |
EPS (Diluted) | -2042.00 | 224.00 | -2595.00 | -1609.47 | -970.00 |
Free Cash Flow | -127,582 | 75,849 | -63,555 | -11,300 | -60,358 |
Free Cash Flow Per Share | -3506.92 | 2182.46 | -2237.54 | -403.33 | -2501.88 |
Gross Margin | 89.01% | 87.33% | 52.12% | 53.42% | 55.04% |
Operating Margin | -75.23% | -16.61% | -236.70% | -150.77% | -86.16% |
Profit Margin | -52.47% | 6.20% | -215.85% | -134.96% | -72.74% |
Free Cash Flow Margin | -90.13% | 60.25% | -186.13% | -33.82% | -187.70% |
EBITDA | -99,877 | -15,905 | -76,150 | -46,257 | -24,658 |
EBITDA Margin | -70.56% | -12.63% | -223.02% | -138.44% | -76.68% |
D&A For EBITDA | 6,609 | 5,009 | 4,672 | 4,118 | 3,049 |
EBIT | -106,486 | -20,913 | -80,822 | -50,375 | -27,707 |
EBIT Margin | -75.23% | -16.61% | -236.70% | -150.77% | -86.16% |
Effective Tax Rate | - | 14.52% | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.